# Dustin J Maly

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 101 papers | 3,149 citations | 31 h-index | 53 g-index |
| 110 ext. papers | 3,746 ext. citations | 7.8 avg, IF | 5.01 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 101 | One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases. *Veterinary Parasitology*, **2021**, 289, 109336 | 2.8 | 5 |
| 100 | Pyrrolopyrimidine Bumped Kinase Inhibitors for the Treatment of Cryptosporidiosis. *ACS Infectious Diseases*, **2021**, 7, 1200-1207 | 5.5 | 1 |
| 99 | ATP-competitive partial antagonists of the IRE1 RNase segregate outputs of the UPR. *Nature Chemical Biology*, **2021**, 17, 1148-1156 | 11.7 | 1 |
| 98 | How ATP-Competitive Inhibitors Allosterically Modulate Tyrosine Kinases That Contain a Src-like Regulatory Architecture. *ACS Chemical Biology*, **2020**, 15, 2005-2016 | 4.9 | 5 |
| 97 | Suppression of unwanted CRISPR-Cas9 editing by co-administration of catalytically inactivating truncated guide RNAs. *Nature Communications*, **2020**, 11, 2697 | 17.4 | 19 |
| 96 | Parallel Chemoselective Profiling for Mapping Protein Structure. *Cell Chemical Biology*, **2020**, 27, 1084-1096.e4 | 8.2 | 2 |
| 95 | Kinobead/LC-MS Phosphokinome Profiling Enables Rapid Analyses of Kinase-Dependent Cell Signaling Networks. *Journal of Proteome Research*, **2020**, 19, 1235-1247 | 5.6 | 2 |
| 94 | Temporal and rheostatic control of genome editing with a chemically-inducible Cas9. *Methods in Enzymology*, **2020**, 633, 119-141 | 1.7 | 0 |
| 93 | A chemically-controlled system for activating RAS GTPases. *Methods in Enzymology*, **2020**, 633, 103-117 | 1.7 | |
| 92 | The Right Tool for the Job: A Chemical and Genetic Toolkit for Interrogating DCLK1 Function. *Cell Chemical Biology*, **2020**, 27, 1221-1223 | 8.2 | 0 |
| 91 | Comparative assessment of the effects of bumped kinase inhibitors on early zebrafish embryo development and pregnancy in mice. *International Journal of Antimicrobial Agents*, **2020**, 56, 106099 | 14.3 | 2 |
| 90 | Pharmacoproteomics Identifies Kinase Pathways that Drive the Epithelial-Mesenchymal Transition and Drug Resistance in Hepatocellular Carcinoma. *Cell Systems*, **2020**, 11, 196-207.e7 | 10.6 | 8 |
| 89 | "Examining RAS pathway rewiring with a chemically inducible activator of RAS". *Small GTPases*, **2020**, 11, 413-420 | 2.7 | 3 |
| 88 | Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned. *International Journal for Parasitology*, **2020**, 50, 413-422 | 4.3 | 21 |
| 87 | Multi-input chemical control of protein dimerization for programming graded cellular responses. *Nature Biotechnology*, **2019**, 37, 1209-1216 | 44.5 | 21 |
| 86 | Chemoproteomic Method for Profiling Inhibitor-Bound Kinase Complexes. *Journal of the American Chemical Society*, **2019**, 141, 11912-11922 | 16.4 | 7 |
| 85 | P-Glycoprotein-Mediated Efflux Reduces the In Vivo Efficacy of a Therapeutic Targeting the Gastrointestinal Parasite Cryptosporidium. *Journal of Infectious Diseases*, **2019**, 220, 1188-1198 | 7 | 6 |

| | | | |
|---|---|---|---|
| 84 | Targeting Dynamic ATP-Binding Site Features Allows Discrimination between Highly Homologous Protein Kinases. *ACS Chemical Biology*, **2019**, 14, 1249-1259 | 4.9 | 9 |
| 83 | Bumped kinase inhibitor 1369 is effective against Cystoisospora suis in vivo and in vitro. *International Journal for Parasitology: Drugs and Drug Resistance*, **2019**, 10, 9-19 | 4 | 7 |
| 82 | A Combined Approach Reveals a Regulatory Mechanism Coupling Src Kinase Activity, Localization, and Phosphotransferase-Independent Functions. *Molecular Cell*, **2019**, 74, 393-408.e20 | 17.6 | 20 |
| 81 | A Chemically Disrupted Proximity System for Controlling Dynamic Cellular Processes. *Journal of the American Chemical Society*, **2019**, 141, 3352-3355 | 16.4 | 8 |
| 80 | Development of a Chemical Toolset for Studying the Paralog-Specific Function of IRE1. *ACS Chemical Biology*, **2019**, 14, 2595-2605 | 4.9 | 8 |
| 79 | Subcellular drug targeting illuminates local kinase action. *ELife*, **2019**, 8, | 8.9 | 17 |
| 78 | Parallel Signaling through IRE1 and PERK Regulates Pancreatic Neuroendocrine Tumor Growth and Survival. *Cancer Research*, **2019**, 79, 6190-6203 | 10.1 | 17 |
| 77 | Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis. *Journal of Infectious Diseases*, **2019**, 219, 1464-1473 | 7 | 8 |
| 76 | Small molecule inhibition of IRE1 kinase/RNase has anti-fibrotic effects in the lung. *PLoS ONE*, **2019**, 14, e0209824 | 3.7 | 30 |
| 75 | Kinome chemoproteomics characterization of pyrrolo[3,4-c]pyrazoles as potent and selective inhibitors of glycogen synthase kinase 3. *Molecular Omics*, **2018**, 14, 26-36 | 4.4 | 9 |
| 74 | In vitro growth inhibition of Theileria equi by bumped kinase inhibitors. *Veterinary Parasitology*, **2018**, 251, 90-94 | 2.8 | 3 |
| 73 | Toxoplasma Calcium-Dependent Protein Kinase 1 Inhibitors: Probing Activity and Resistance Using Cellular Thermal Shift Assays. *Antimicrobial Agents and Chemotherapy*, **2018**, 62, | 5.9 | 11 |
| 72 | 7 H-Pyrrolo[2,3- d]pyrimidin-4-amine-Based Inhibitors of Calcium-Dependent Protein Kinase 1 Have Distinct Inhibitory and Oral Pharmacokinetic Characteristics Compared with 1 H-Pyrazolo[3,4-d]pyrimidin-4-amine-Based Inhibitors. *ACS Infectious Diseases*, **2018**, 4, 516-522 | 5.5 | 5 |
| 71 | Rheostatic Control of Cas9-Mediated DNA Double Strand Break (DSB) Generation and Genome Editing. *ACS Chemical Biology*, **2018**, 13, 438-442 | 4.9 | 8 |
| 70 | Allosteric Modulation of JNK Docking Site Interactions with ATP-Competitive Inhibitors. *Biochemistry*, **2018**, 57, 5897-5909 | 3.2 | 8 |
| 69 | Kinobead and Single-Shot LC-MS Profiling Identifies Selective PKD Inhibitors. *Journal of Proteome Research*, **2017**, 16, 1216-1227 | 5.6 | 25 |
| 68 | Extended-spectrum antiprotozoal bumped kinase inhibitors: A review. *Experimental Parasitology*, **2017**, 180, 71-83 | 2.1 | 39 |
| 67 | Two Novel Calcium-Dependent Protein Kinase 1 Inhibitors Interfere with Vertical Transmission in Mice Infected with Neospora caninum Tachyzoites. *Antimicrobial Agents and Chemotherapy*, **2017**, 61, | 5.9 | 16 |

| | | | |
|---|---|---|---|
| 66 | Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 2334-2341 | 5.1 | 30 |
| 65 | 5-Aminopyrazole-4-Carboxamide-Based Compounds Prevent the Growth of Cryptosporidium parvum. *Antimicrobial Agents and Chemotherapy*, **2017**, 61, | 5.9 | 14 |
| 64 | Targeting ABL-IRE1 Signaling Spares ER-Stressed Pancreatic Cells to Reverse Autoimmune Diabetes. *Cell Metabolism*, **2017**, 25, 883-897.e8 | 24.6 | 107 |
| 63 | Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy. *Journal of Infectious Diseases*, **2017**, 215, 1275-1284 | 7 | 42 |
| 62 | In vitro efficacy of bumped kinase inhibitors against Besnoitia besnoiti tachyzoites. *International Journal for Parasitology*, **2017**, 47, 811-821 | 4.3 | 16 |
| 61 | Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis. *International Journal for Parasitology*, **2017**, 47, 753-763 | 4.3 | 22 |
| 60 | Rapidly inducible Cas9 and DSB-ddPCR to probe editing kinetics. *Nature Methods*, **2017**, 14, 891-896 | 21.6 | 56 |
| 59 | Necessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium Infection. *Journal of Infectious Diseases*, **2017**, 216, 55-63 | 7 | 34 |
| 58 | A computationally engineered RAS rheostat reveals RAS-ERK signaling dynamics. *Nature Chemical Biology*, **2017**, 13, 119-126 | 11.7 | 15 |
| 57 | Profiling the Dual Enzymatic Activities of the Serine/Threonine Kinase IRE1 *Methods in Molecular Biology*, **2017**, 1513, 233-242 | 1.4 | 1 |
| 56 | Allosteric Modulation of Src Family Kinases with ATP-Competitive Inhibitors. *Methods in Molecular Biology*, **2017**, 1636, 79-89 | 1.4 | 2 |
| 55 | Proteomic Profiling of Protein Kinase Inhibitor Targets by Mass Spectrometry. *Methods in Molecular Biology*, **2017**, 1636, 105-117 | 1.4 | 4 |
| 54 | Selective inhibition of Sarcocystis neurona calcium-dependent protein kinase 1 for equine protozoal myeloencephalitis therapy. *International Journal for Parasitology*, **2016**, 46, 871-880 | 4.3 | 17 |
| 53 | 5-Aminopyrazole-4-carboxamide analogues are selective inhibitors of Plasmodium falciparum microgametocyte exflagellation and potential malaria transmission blocking agents. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 5487-5491 | 2.9 | 14 |
| 52 | Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis. *Journal of Medicinal Chemistry*, **2016**, 59, 6531-46 | 8.3 | 68 |
| 51 | Structural and Functional Analysis of the Allosteric Inhibition of IRE1 with ATP-Competitive Ligands. *ACS Chemical Biology*, **2016**, 11, 2195-205 | 4.9 | 50 |
| 50 | Bumped kinase inhibitor prohibits egression in Babesia bovis. *Veterinary Parasitology*, **2016**, 215, 22-8 | 2.8 | 16 |
| 49 | Conversion of a Single Polypharmacological Agent into Selective Bivalent Inhibitors of Intracellular Kinase Activity. *ACS Chemical Biology*, **2016**, 11, 121-31 | 4.9 | 12 |

| | | | |
|---|---|---|---|
| 48 | Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds. *PLoS ONE*, **2016**, 11, e0149996 | 3.7 | 34 |
| 47 | Reduced Activity of Mutant Calcium-Dependent Protein Kinase 1 Is Compensated in Plasmodium falciparum through the Action of Protein Kinase G. *MBio*, **2016**, 7, | 7.8 | 25 |
| 46 | Novel Bumped Kinase Inhibitors Are Safe and Effective Therapeutics in the Calf Clinical Model for Cryptosporidiosis. *Journal of Infectious Diseases*, **2016**, 214, 1856-1864 | 7 | 43 |
| 45 | A novel protein kinase is essential in bloodstream Trypanosoma brucei. *International Journal for Parasitology*, **2016**, 46, 479-83 | 4.3 | 4 |
| 44 | SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues as Potent and Selective Inhibitors of CDPK1. *ACS Medicinal Chemistry Letters*, **2015**, 6, 1184-1189 | 4.3 | 27 |
| 43 | Radiotherapy followed by aurora kinase inhibition targets tumor-propagating cells in human glioblastoma. *Molecular Cancer Therapeutics*, **2015**, 14, 419-28 | 6.1 | 20 |
| 42 | In Vitro and In Vivo Effects of the Bumped Kinase Inhibitor 1294 in the Related Cyst-Forming Apicomplexans Toxoplasma gondii and Neospora caninum. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 6361-74 | 5.9 | 47 |
| 41 | Potent and selective inhibitors of CDPK1 from and based on a 5-aminopyrazole-4-carboxamide scaffold. *ACS Medicinal Chemistry Letters*, **2014**, 5, 40-44 | 4.3 | 42 |
| 40 | Rapid profiling of protein kinase inhibitors by quantitative proteomics. *MedChemComm*, **2014**, 5, 363-369 | 3 | 17 |
| 39 | A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation. *Journal of Infectious Diseases*, **2014**, 209, 275-84 | 7 | 75 |
| 38 | SH2-catalytic domain linker heterogeneity influences allosteric coupling across the SFK family. *Biochemistry*, **2014**, 53, 6910-23 | 3.2 | 19 |
| 37 | Druggable sensors of the unfolded protein response. *Nature Chemical Biology*, **2014**, 10, 892-901 | 11.7 | 153 |
| 36 | Bivalent inhibitors of protein kinases. *Critical Reviews in Biochemistry and Molecular Biology*, **2014**, 49, 102-15 | 8.7 | 42 |
| 35 | Divergent modulation of Src-family kinase regulatory interactions with ATP-competitive inhibitors. *ACS Chemical Biology*, **2014**, 9, 1894-905 | 4.9 | 19 |
| 34 | Allosteric inhibition of the IRE1□RNase preserves cell viability and function during endoplasmic reticulum stress. *Cell*, **2014**, 158, 534-48 | 56.2 | 297 |
| 33 | Conformation-selective ATP-competitive inhibitors control regulatory interactions and noncatalytic functions of mitogen-activated protein kinases. *Chemistry and Biology*, **2014**, 21, 628-35 | | 24 |
| 32 | Development of potent and selective Plasmodium falciparum calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that block the transmission of malaria to mosquitoes. *European Journal of Medicinal Chemistry*, **2014**, 74, 562-73 | 6.8 | 44 |
| 31 | Bumped kinase inhibitor 1294 treats established Toxoplasma gondii infection. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 3547-9 | 5.9 | 56 |

| | | | |
|---|---|---|---|
| 30 | The gatekeeper residue and beyond: homologous calcium-dependent protein kinases as drug development targets for veterinarian Apicomplexa parasites. *Parasitology*, **2014**, 141, 1499-1509 | 2.7 | 40 |
| 29 | Neospora caninum calcium-dependent protein kinase 1 is an effective drug target for neosporosis therapy. *PLoS ONE*, **2014**, 9, e92929 | 3.7 | 48 |
| 28 | Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src. *ACS Chemical Biology*, **2013**, 8, 2734-43 | 4.9 | 24 |
| 27 | Label transfer reagents to probe p38 MAPK binding partners. *ChemBioChem*, **2013**, 14, 209-16 | 3.8 | 6 |
| 26 | Active site profiling reveals coupling between domains in SRC-family kinases. *Nature Chemical Biology*, **2013**, 9, 43-50 | 11.7 | 50 |
| 25 | A hexylchloride-based catch-and-release system for chemical proteomic applications. *ACS Chemical Biology*, **2013**, 8, 691-9 | 4.9 | 15 |
| 24 | Sequence determinants of a specific inactive protein kinase conformation. *Chemistry and Biology*, **2013**, 20, 806-15 | | 62 |
| 23 | A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis. *Journal of Infectious Diseases*, **2013**, 208, 1342-8 | 7 | 55 |
| 22 | Calcium-Dependent Protein Kinases of Apicomplexan Parasites as Drug Targets **2013**, 293-316 | | 1 |
| 21 | Investigating inactive conformations of protein kinases. *FASEB Journal*, **2013**, 27, 1042.1 | 0.9 | |
| 20 | Affinity-based probes based on type II kinase inhibitors. *Journal of the American Chemical Society*, **2012**, 134, 19017-25 | 16.4 | 41 |
| 19 | Targeting diverse signaling interaction sites allows the rapid generation of bivalent kinase inhibitors. *ACS Chemical Biology*, **2012**, 7, 487-95 | 4.9 | 22 |
| 18 | Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1. *Journal of Medicinal Chemistry*, **2012**, 55, 2803-10 | 8.3 | 56 |
| 17 | Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity. *Journal of Medicinal Chemistry*, **2012**, 55, 2416-26 | 8.3 | 88 |
| 16 | Divergent allosteric control of the IRE1endoribonuclease using kinase inhibitors. *Nature Chemical Biology*, **2012**, 8, 982-9 | 11.7 | 147 |
| 15 | Transmission of malaria to mosquitoes blocked by bumped kinase inhibitors. *Journal of Clinical Investigation*, **2012**, 122, 2301-5 | 15.9 | 81 |
| 14 | Label Transfer Reagents for the Study of Protein Kinase Complexes. *FASEB Journal*, **2012**, 26, 755.3 | 0.9 | |
| 13 | Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 4951-5 | 2.9 | 3 |

# List of Publications

| | | | |
|---|---|---|---|
| 12 | Bivalent inhibitors of the tyrosine kinases ABL and SRC: determinants of potency and selectivity. *Molecular BioSystems*, **2011**, 7, 447-56 | | 12 |
| 11 | Discovery of Potent and Selective Inhibitors of Calcium-Dependent Protein Kinase 1 (CDPK1) from C. parvum and T. gondii. *ACS Medicinal Chemistry Letters*, **2010**, 1, 331-335 | 4.3 | 110 |
| 10 | A small molecule-regulated guanine nucleotide exchange factor. *Journal of the American Chemical Society*, **2010**, 132, 938-40 | 16.4 | 21 |
| 9 | Intracellular delivery of bioactive molecules using light-addressable nanocapsules. *ACS Nano*, **2010**, 4, 7603-11 | 16.7 | 29 |
| 8 | Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. *Nature Structural and Molecular Biology*, **2010**, 17, 602-7 | 17.6 | 144 |
| 7 | Affinity reagents that target a specific inactive form of protein kinases. *Chemistry and Biology*, **2010** , 17, 195-206 | | 31 |
| 6 | Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. *Cancer Research*, **2009**, 69, 2384-92 | 10.1 | 117 |
| 5 | A chemical genetic method for generating bivalent inhibitors of protein kinases. *Journal of the American Chemical Society*, **2009**, 131, 6686-8 | 16.4 | 30 |
| 4 | Design, synthesis and characterization of "clickable" 4-anilinoquinazoline kinase inhibitors. *Molecular BioSystems*, **2008**, 4, 542-50 | | 7 |
| 3 | Exploring the intermembrane space. *ACS Chemical Biology*, **2007**, 2, 213-6 | 4.9 | 2 |
| 2 | Chemical genomic and proteomic methods for determining kinase inhibitor selectivity. *Combinatorial Chemistry and High Throughput Screening*, **2007**, 10, 652-66 | 1.3 | 16 |
| 1 | Protocol for rapidly inducible Cas9 and DSB-ddPCR. *Protocol Exchange*, | | 2 |